Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ertugliflozin

FDA-approved product (tablet, oral), marketed as Ertugliflozin, Steglatro.

Registered studies
49
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ertugliflozin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Ertugliflozin. Its therapeutic class is shown instead.

WHO therapeutic group
Sodium-glucose co-transporter 2 (sglt2) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ertugliflozin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ertugliflozin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

    NCT01059825 · start 2010-02-24

    Registered record
    Registry ID
    NCT01059825
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Placebo to Ertugliflozin; Ertugliflozin 1 mg; Ertugliflozin 5 mg; Ertugliflozin 25 mg; Sitagliptin 100 mg; Placebo to Sitagliptin; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-02-24
    Completion
    2011-01-20
    Enrolment
    375

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionPlacebo to Ertugliflozin; Ertugliflozin 1 mg; Ertugliflozin 5 mg; Ertugliflozin 25 mg +3 more
    PhasePhase 2
    Registry statusCompleted

  • Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)

    NCT01054300 · start 2010-02-17

    Registered record
    Registry ID
    NCT01054300
    Conditions
    Diabetes Mellitus, Type 2; Adult
    Interventions
    Ertugliflozin 2 mg single dose; Ertugliflozin 2 mg split into twice daily; Ertugliflozin 4 mg single dose; Ertugliflozin 4 mg split into twice daily; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-02-17
    Completion
    2010-04-07
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Adult
    InterventionErtugliflozin 2 mg single dose; Ertugliflozin 2 mg split into twice daily; Ertugliflozin 4 mg single dose; Ertugliflozin 4 mg split into twice daily +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)

    NCT01018823 · start 2009-12-14

    Registered record
    Registry ID
    NCT01018823
    Conditions
    Healthy Volunteer
    Interventions
    Ertugliflozin; Placebo to Ertugliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-12-14
    Completion
    2010-03-18
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionErtugliflozin; Placebo to Ertugliflozin
    PhasePhase 1
    Registry statusCompleted

  • A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)

    NCT00989079 · start 2009-10-16

    Registered record
    Registry ID
    NCT00989079
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Ertugliflozin; Placebo to Ertugliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-10-16
    Completion
    2009-12-11
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionErtugliflozin; Placebo to Ertugliflozin
    PhasePhase 1
    Registry statusCompleted